Persons with non-A, non-B hepatitis (cases) identified in 5 transfusion studies in the early 1970s have been followed ever since and compared for outcome with matched, transfused, non-hepatitis controls from the same studies. Previously, we reported no difference in all-cause mortality but slightly increased liver-related mortality between these cohorts after 18 years follow-up. We now present mortality and morbidity data after approximately 25 years of followup, restricted to the 3 studies with archived original sera. All-cause mortality was 67% among 222 hepatitis C-related cases and 65% among 377 controls (P ؍ NS). Liver-related mortality was 4.1% and 1.3%, respectively (P ؍ . Acute non-A, non-B hepatitis, attributable predominantly to hepatitis C virus (HCV) infection, is usually a mild and asymptomatic illness. 1 Nevertheless, more than 80% of such persons develop persistent infection and most have biochemical evidence of chronic hepatitis.